Yang PM - Search Results

1

Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase.

Lin JC, Liu TP, Chen YB, Huang TS, Chen TY, Yang PM. Lin JC, et al. Among authors: yang pm. Toxicol Appl Pharmacol. 2023 Jul 15;471:116568. doi: 10.1016/j.taap.2023.116568. Epub 2023 May 27. Toxicol Appl Pharmacol. 2023. PMID: 37245555

2

S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.

Liu TP, Lo HL, Wei LS, Hsiao HH, Yang PM. Liu TP, et al. Among authors: yang pm. Anticancer Drugs. 2015 Feb;26(2):139-47. doi: 10.1097/CAD.0000000000000166. Anticancer Drugs. 2015. PMID: 25203626 Free PMC article.

3

In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes.

Liu TP, Hong YH, Tung KY, Yang PM. Liu TP, et al. Among authors: yang pm. Oncoscience. 2016 Jan 29;3(1):9-20. doi: 10.18632/oncoscience.285. eCollection 2016. Oncoscience. 2016. PMID: 26973856 Free PMC article.

4

In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells.

Liu TP, Hong YH, Yang PM. Liu TP, et al. Among authors: yang pm. Oncotarget. 2017 Sep 16;8(49):86168-86180. doi: 10.18632/oncotarget.21030. eCollection 2017 Oct 17. Oncotarget. 2017. PMID: 29156785 Free PMC article.

5

Systematic polypharmacology and drug repurposing via an integrated L1000-based Connectivity Map database mining.

Liu TP, Hsieh YY, Chou CJ, Yang PM. Liu TP, et al. Among authors: yang pm. R Soc Open Sci. 2018 Nov 28;5(11):181321. doi: 10.1098/rsos.181321. eCollection 2018 Nov. R Soc Open Sci. 2018. PMID: 30564416 Free PMC article.

6

In silico repurposing the Rac1 inhibitor NSC23766 for treating PTTG1-high expressing clear cell renal carcinoma.

Hsieh YY, Liu TP, Yang PM. Hsieh YY, et al. Among authors: yang pm. Pathol Res Pract. 2019 Jun;215(6):152373. doi: 10.1016/j.prp.2019.03.002. Epub 2019 Mar 4. Pathol Res Pract. 2019. PMID: 30871916

7

Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.

Hsieh YY, Liu TP, Chou CJ, Chen HY, Lee KH, Yang PM. Hsieh YY, et al. Among authors: yang pm. Genes (Basel). 2019 Sep 28;10(10):766. doi: 10.3390/genes10100766. Genes (Basel). 2019. PMID: 31569425 Free PMC article.

8

p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma.

Yang PM, Hong YH, Hsu KC, Liu TP. Yang PM, et al. Am J Cancer Res. 2019 Oct 1;9(10):2120-2139. eCollection 2019. Am J Cancer Res. 2019. PMID: 31720078 Free PMC article.

9

Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.

Yang PM, Lin LS, Liu TP. Yang PM, et al. Biomolecules. 2020 Jan 9;10(1):117. doi: 10.3390/biom10010117. Biomolecules. 2020. PMID: 31936661 Free PMC article.

10

CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study.

Lin JC, Liu TP, Yang PM. Lin JC, et al. Among authors: yang pm. J Clin Med. 2020 Dec 12;9(12):4019. doi: 10.3390/jcm9124019. J Clin Med. 2020. PMID: 33322698 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

265 results

Search Page

Filters